Precigen

Compare

1,168 Followers

PGEN Stock Chart & Stats

$4.01

-$0.11(-8.33%)

At close: Jan 08 4:00 PM EST

$4.01

-$0.11(-8.33%)

Day’s Range― - ―

52-Week Range$0.65 - $5.23

Previous CloseN/A

Volume729.99K

Average Volume (3M)5.48M

Market Cap

$1.21B

Enterprise Value$397.22M

Total Cash (Recent Filing)$59.75M

Total Debt (Recent Filing)$5.15M

Price to Earnings (P/E)―

Beta2.00

Next Earnings

Nov 12, 2025

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding297,972,930

10 Day Avg. Volume5,121,596

30 Day Avg. Volume5,477,108

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue91.53

Enterprise Value/Gross Profit-1.14K

Enterprise Value/Ebitda-3.26

Forecast

1Y Price Target

$8.25

Price Target Upside105.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial OutlookThe analyst raised the 12-month price target to $8.50 per diluted share from prior $6 due to the announcement of the approval.

Market StrategyThe commercial team is expected to target 93 Integrated Delivery Networks and community hospitals, reaching nearly 80% of the prescribing physician base, indicating a strong market strategy.

Regulatory ApprovalPapzimeos received full FDA approval as a therapy for the treatment of adults with recurrent respiratory papillomatosis, which was better than expected and announced earlier than the PDUFA action date.

Bears Say

Precigen News

Precigen presents long-term data demonstrating durable responses to PAPZIMEOS

Precigen (PGEN) announced long-term follow-up data demonstrating durable responses to PAPZIMEOS for the treatment of adults with recurrent...

18d ago

PGEN

Precigen’s Promising Phase 2 Study: PRGN-2009 and Pembrolizumab for Cervical Cancer

Precigen, Inc. (($PGEN)) announced an update on their ongoing clinical study. Precigen, Inc. is conducting a Phase 2...

4d ago

PGEN

Precigen Converts Preferred Stock to Common Shares

An announcement from Precigen ( ($PGEN) ) is now available. On September 15, 2025, Precigen, Inc. saw the...

1M ago

PGEN

Precigen Secures $125M Loan for PAPZIMEOS Expansion

Precigen ( ($PGEN) ) just unveiled an announcement. On September 3, 2025, Precigen, Inc. announced a loan agreement...

2M ago

PGEN

Precigen files to sell 143.81M shares of common stock for holders

17:33 EDT Precigen (PGEN) files to sell 143.81M shares of common stock for holders Published first on TheFly...

2M ago

PGEN

Buy Rating for Precigen: Strong Market Potential and Strategic Positioning of Papzimeos

Swayampakula Ramakanth, an analyst from H.C. Wainwright, reiterated the Buy rating on Precigen. The associated price target remains...

2M ago

PGEN

Precigen price target raised to $8 from $6 at Citizens JMP

Citizens JMP raised the firm’s price target on Precigen (PGEN) to $8 from $6 and keeps an Outperform...

2M ago

PGEN

Precigen Enters Commercial Supply Agreement with Catalent

Precigen ( ($PGEN) ) has shared an update. On August 13, 2025, Precigen, Inc. entered into a Commercial...

2M ago

PGEN

Unusually active option classes on open August 18th

Unusual total active option classes on open include: iQiyi (IQ), First Solar (FSLR), ProShares Morningstar Alternatives Solution ETF...

2M ago

Precigen’s PAPZIMEOS Receives FDA Approval for RRP

An update from Precigen ( ($PGEN) ) is now available. On August 18, 2025, Precigen, Inc. announced that...

2M ago

PGEN

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

It’s time to dive into the biggest stock market stories with all of the hottest news from Friday! ...

3M ago

AMD

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy

Shares in biopharmaceutical company Precigen ($PGEN) rocketed higher today after the U.S. Food and Drug Administration gave the...

3M ago

PGEN

Berkshire takes stake in UnitedHealth, Sandisk reports Q4 beat; Morning Buzz

The major averages were mixed near noon as traders digest new hedge fund holdings following yesterday’s 13F filing...

3M ago

Morning Movers: Precigen surges following full FDA approval of Papzimeos

S&P 500 index futures are up 0.1% as U.S. retail sales rose in July, but less than expected....

3M ago

DHI

FLO

PGEN FAQ

What was Precigen’s price range in the past 12 months?

Precigen lowest stock price was $0.65 and its highest was $5.22 in the past 12 months.

What is Precigen’s market cap?

Precigen’s market cap is $1.21B.

When is Precigen’s upcoming earnings report date?

Precigen’s upcoming earnings report date is Nov 12, 2025 which is in 12 days.

How were Precigen’s earnings last quarter?

Precigen released its earnings results on Aug 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.003.

Is Precigen overvalued?

According to Wall Street analysts Precigen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Precigen pay dividends?

Precigen does not currently pay dividends.

What is Precigen’s EPS estimate?

Precigen’s EPS estimate is -0.09.

How many shares outstanding does Precigen have?

Precigen has 297,972,930 shares outstanding.

What happened to Precigen’s price movement after its last earnings report?

Precigen reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 3.448%.

Which hedge fund is a major shareholder of Precigen?

Currently, no hedge funds are holding shares in PGEN

Precigen Stock Smart Score

Neutral

Fundamentals

Return on Equity

-668.03%

Trailing 12-Months

Asset Growth

39.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Precigen

Precigen (PGEN) is a biotechnology company focused on harnessing the power of gene and cell therapies to develop transformative treatments for cancer and other genetic disorders. Operating within the life sciences sector, Precigen utilizes its proprietary technology platforms, including UltraCar-T and Precigen's gene delivery systems, to create innovative therapeutic solutions. The company's core products include engineered T-cell therapies and other advanced biologics designed to improve patient outcomes in oncology and other areas of unmet medical need.

Precigen (PGEN) Earnings & Revenues

Historic Earnings Reports

PGEN Stock 12 Month Forecast

Average Price Target

$8.25

▲(105.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.76,5.047692307692308,5.335384615384616,5.623076923076923,5.9107692307692306,6.1984615384615385,6.4861538461538455,6.773846153846153,7.061538461538461,7.349230769230769,7.636923076923077,7.924615384615384,8.212307692307693,{"y":8.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.76,5.0284615384615385,5.296923076923076,5.565384615384615,5.833846153846154,6.102307692307692,6.3707692307692305,6.639230769230769,6.907692307692308,7.176153846153846,7.444615384615385,7.7130769230769225,7.981538461538461,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.76,5.009230769230769,5.258461538461538,5.507692307692308,5.756923076923076,6.006153846153846,6.2553846153846155,6.504615384615384,6.753846153846154,7.003076923076923,7.252307692307692,7.501538461538462,7.750769230769231,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >